A SARS-CoV-2 sublineage called BA.3.2, nicknamed the “Cicada” variant, has been detected in wastewater samples across 25 U.S. states, raising fresh questions about COVID-19’s trajectory heading into spring 2026. First identified in South Africa in late 2024, BA.3.2 circulated at low levels for months before gaining enough traction to register in domestic surveillance systems. Its emergence now, after more than a year of quiet circulation, has drawn attention from both the CDC and the World Health Organization, and the variant’s ability to partially evade existing immunity makes it a strain worth watching closely.
From South Africa to U.S. Sewage
BA.3.2 was first identified in South Africa on November 22, 2024, according to a CDC Morbidity and Mortality Weekly Report that has since been summarized in a peer‑reviewed analysis of emerging variants. That timeline creates a gap of roughly 16 months between initial detection abroad and the variant’s current spread across multiple U.S. states. A separate account from Northeastern University describes BA.3.2 as having been on public‑health radar for almost 15 months before late March 2026, a slight discrepancy that likely reflects different reference points for when the variant entered formal tracking versus when it was first sequenced.
The “Cicada” nickname itself is telling. Like the insect that spends years underground before surfacing in large numbers, BA.3.2 persisted at low prevalence globally before accelerating in late 2025 and early 2026. That pattern challenges a common assumption in public discussions about COVID variants: that a new lineage either takes off quickly or fades into irrelevance. BA.3.2 did neither for over a year, then gained ground, illustrating how SARS‑CoV‑2 can linger beneath detection thresholds before conditions shift in its favor.
How Wastewater Tracking Spotted the Spread
The detection of BA.3.2 across 25 states relies heavily on the CDC’s National Wastewater Surveillance System, which monitors sewage samples for fragments of SARS‑CoV‑2 genetic material. When public health officials say a variant has been “detected in wastewater,” that means sequencing has identified its genetic signature in community sewage, not that confirmed clinical cases have been tallied in each state. This distinction matters because wastewater data often signals rising transmission weeks before hospital admissions or test‑positivity rates reflect the same trend.
The technical backbone of this surveillance is substantial. A peer‑reviewed article in the CDC’s Emerging Infectious Diseases journal describes how wastewater sequencing pipelines estimate each lineage’s relative abundance through alignment to a reference genome, deconvolution software, and phylogenetic barcodes. Although that study focused on the JN.1 lineage retrospectively, the same methods now apply to BA.3.2 tracking, allowing scientists to infer shifts in variant dominance even when clinical testing is patchy or at‑home tests go unreported.
Genome sequence data from these efforts flow into public repositories where researchers worldwide can access and analyze them, helping to corroborate domestic findings. When the same BA.3.2 signatures appear in multiple independent wastewater systems, confidence grows that the variant’s spread is genuine and not a sequencing artifact. For local officials, a steady uptick in BA.3.2’s share of wastewater reads can function as a de facto early‑warning dashboard, signaling when to prepare hospitals, refresh public messaging, or encourage higher‑risk residents to take extra precautions.
Airport Surveillance as an Early Warning System
Domestic wastewater monitoring was not the only tool that flagged BA.3.2. The CDC’s Traveler‑Based Genomic Surveillance program collects voluntary nasal swabs from arriving international passengers and analyzes airplane wastewater and airport triturator samples, creating a snapshot of what travelers are bringing into the country. Triturators are consolidation points in airport plumbing systems where waste from multiple aircraft is combined, giving researchers a pooled sample that can reveal new variants even when individual case counts are still low.
This layered approach, pairing airport‑level sampling with community sewage monitoring, creates an early detection window that clinical testing alone cannot match. If BA.3.2 detections at major international gateways consistently preceded community‑level wastewater signals by several weeks, that would suggest targeted expansion of airport sampling could buy public health agencies meaningful lead time before a variant wave builds domestically. Specific airport‑level sequence counts for BA.3.2 from the traveler surveillance program have not been publicly released for March 2026 onward, so the exact size of that lead time remains unclear, but the strategy underscores how mobility patterns and genomics now intersect in real‑time surveillance.
What “Moderate Immune Escape” Means for Protection
The CDC’s 2025‑2026 Respiratory Disease Season Outlook, updated in December 2025, characterized BA.3.2 as having moderate immune‑escape features. That language sits between reassuring and alarming. It means BA.3.2 carries enough mutations to partially dodge antibodies generated by prior infection or vaccination, but not so many that existing immunity is rendered useless. People who are up to date on COVID‑19 vaccines or who have had recent infections likely retain meaningful protection against severe illness, though breakthrough infections become more probable, especially months after their last dose or infection.
Laboratory assays that measure how well antibodies neutralize BA.3.2 compared with earlier strains underpin this assessment. A drop in neutralization does not translate directly into a proportional drop in real‑world protection, because immune memory involves T cells and other mechanisms that are less affected by spike‑protein changes. Still, moderate immune escape raises the odds of symptomatic infection and reinfection, particularly among people with waning immunity or underlying conditions.
No primary CDC data on confirmed clinical cases or hospitalization rates specifically attributable to BA.3.2 in the U.S. have been published as of late March 2026. That gap limits how confidently anyone can assess the variant’s real‑world severity. Wastewater prevalence and immune‑escape lab data tell part of the story, but without clinical outcome numbers, the practical risk to individuals remains harder to quantify than headlines might suggest. For now, experts emphasize that core risk‑reduction strategies, staying current on vaccines, improving indoor ventilation, and using masks in crowded indoor settings during surges, still apply.
Global Monitoring and Vaccine Implications
BA.3.2’s rise is unfolding against a backdrop of ongoing international deliberations about COVID‑19 vaccine composition. The World Health Organization has outlined the types of variant data it seeks ahead of decisions on future vaccine antigens, including genomic surveillance, antigenic characterization, and vaccine effectiveness studies. Variants that show both significant immune escape and sustained transmission are most likely to influence those deliberations.
For BA.3.2, the key questions are whether its moderate immune escape translates into notable drops in vaccine performance and whether it displaces other circulating lineages over time. If BA.3.2 becomes a dominant strain globally or clusters with other related lineages in a distinct antigenic “family,” vaccine advisory groups could consider updating formulations to better match its spike‑protein profile. Conversely, if BA.3.2 remains one of several co‑circulating variants with only modest growth advantages, existing vaccines may continue to offer sufficient protection against severe disease without an immediate overhaul.
Global monitoring also matters for equity. Countries with limited clinical testing capacity may rely disproportionately on wastewater and airport‑based surveillance to spot BA.3.2 and similar variants. Sharing sequences, immune‑escape data, and vaccine‑effectiveness findings through international networks helps ensure that lower‑resource settings are not the last to know when the viral landscape shifts.
Staying Informed Without Overreacting
For individuals, the emergence of BA.3.2 is less a call for panic than a reminder that SARS‑CoV‑2 continues to evolve. Public health agencies are trying to make it easier for people to track these developments. The CDC offers email updates on respiratory threats, including variant assessments, through its subscription service, which can help clinicians, local officials, and interested members of the public stay abreast of changing guidance.
Reaching diverse communities is a parallel priority. Many COVID‑19 resources, including information on vaccination and respiratory‑virus prevention, are available in multiple languages through the CDC’s multilingual library. Ensuring that updates on BA.3.2 and other variants are accessible to non‑English speakers is crucial for equitable risk communication, especially in areas where language barriers have historically limited access to health information.
As BA.3.2’s trajectory becomes clearer in the coming months, the same tools that detected its quiet rise (wastewater monitoring, traveler‑based surveillance, and global genomic sharing) will shape how health authorities respond. For now, experts stress that the fundamentals remain unchanged: vaccination still reduces the risk of severe COVID‑19, ventilation and masking can cut exposure during surges, and staying informed through reliable sources is the best antidote to both complacency and alarm. The “Cicada” variant is a reminder not that the pandemic is starting over, but that the virus has not stopped adapting, and neither should the systems built to track and counter it.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
